Payment overview · 2025
General Payments
$1,033.03
64 reported records · 13 companies
Healthcare provider profile · identity verified
Mario Celaya, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · LINDSAY, CA · NPI 1124173786
Verified facts
What the public records show
CMS Open Payments records show Mario Celaya, P.A. received $1,033.03 in general payments during 2025 across 64 reported records.
Lilly USA, LLC accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 259 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $249.73 | 24.2% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $172.39 | 16.7% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $163.57 | 15.8% | 21 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.06 | 10.5% | 8 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $85.00 | 8.2% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $53.89 | 5.2% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.06 | 5.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.66 | 4.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $38.13 | 3.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.05 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.27 | 1.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.07 | 1.5% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $14.15 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $948.03 | 62 |
| Education | $85.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $225.64 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $118.69 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $108.06 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $90.62 | 9 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $89.20 | 13 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $85.00 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.67 | 7 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $53.89 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $53.06 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.11 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.59 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.59 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $38.13 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $12.07 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 87 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 184 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 85 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 111 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 94 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 259 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
38 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 22 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
111 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
94 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
259 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
92 | 18 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
184 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 146 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 263 | 40 |
| Ozempic | Semaglutide | 259 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 257 | 35 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 257 | 41 |
| Lisinopril | Lisinopril | 221 | 80 |
| Omeprazole | Omeprazole | 203 | 98 |
| Diclofenac Sodium | Diclofenac Sodium | 196 | 75 |
| Gemtesa | Vibegron | 184 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 176 | 56 |
| Celecoxib | Celecoxib | 151 | 76 |
| Ibuprofen | Ibuprofen | 150 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 138 | 48 |
| Linzess | Linaclotide | 137 | 37 |
| Metformin Hcl | Metformin Hcl | 122 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 51 |
| Alprazolam | Alprazolam | 112 | 38 |
| Kerendia | Finerenone | 111 | 26 |
| Losartan Potassium | Losartan Potassium | 104 | 39 |
| Repatha Sureclick | Evolocumab | 104 | 20 |
| Tramadol Hcl | Tramadol Hcl | 102 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 27 |
| Mounjaro | Tirzepatide | 94 | 14 |
| Rybelsus | Semaglutide | 92 | 18 |
| Farxiga | Dapagliflozin Propanediol | 87 | 22 |
| Jardiance | Empagliflozin | 85 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 44 |
| Meclizine Hcl | Meclizine Hcl | 76 | 38 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 75 | 32 |
| Montelukast Sodium | Montelukast Sodium | 74 | 39 |
| Naproxen | Naproxen | 73 | 41 |
| Fluconazole | Fluconazole | 70 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 30 |
| Benazepril Hcl | Benazepril Hcl | 66 | 21 |
| Prednisone | Prednisone | 64 | 44 |
| Gabapentin | Gabapentin | 62 | 24 |
| Furosemide | Furosemide | 61 | 25 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 60 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 52 |
| Azithromycin | Azithromycin | 55 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 28 |
| Carvedilol | Carvedilol | 49 | 18 |
| Clonazepam | Clonazepam | 45 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Famotidine | Famotidine | 42 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 17 |
| Synjardy | Empagliflozin/Metformin Hcl | 41 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 39 | 32 |
| Prolia | Denosumab | 38 | 31 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 20 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Finasteride | Finasteride | 34 | 13 |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 12 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 32 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 32 | 16 |
| Hydrocortisone | Hydrocortisone | 31 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 30 | 15 |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 29 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | 11 |
| Advocate Pen Needles | Pen Needle, Diabetic | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | 12 |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 14 |
| Dutasteride | Dutasteride | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | 11 |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Segluromet | Ertugliflozin/Metformin | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,033.03 · 64 records | Lilly USA, LLC | AFREZZA, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, Doc Band, FARXIGA, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, REPATHA, Rybelsus, TEZSPIRE, VOQUEZNA, Wegovy, XYOSTED, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error